Priority covid-19 vaccination for patients with cancer while vaccine supply is limited

Antoni Ribas; Rajarshi Sengupta; Trevan Locke; Sayyed Kaleem Zaidi; Katie M. Campbell; John M. Carethers; Elizabeth M. Jaffee; E. John Wherry; Jean Charles Soria; Gypsyamber D’souza

doi:10.1158/2159-8290.CD-20-1817

Priority covid-19 vaccination for patients with cancer while vaccine supply is limited

Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed Kaleem Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean Charles Soria, Gypsyamber D’souza

School of Medicine

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

Original language	English (US)
Pages (from-to)	233-236
Number of pages	4
Journal	Cancer discovery
Volume	11
Issue number	2
DOIs	https://doi.org/10.1158/2159-8290.CD-20-1817
State	Published - Feb 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.1158/2159-8290.CD-20-1817

Cite this

@article{ea3a067736f04cdeb1bd0c5b24f6f697,

title = "Priority covid-19 vaccination for patients with cancer while vaccine supply is limited",

abstract = "Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.",

author = "Antoni Ribas and Rajarshi Sengupta and Trevan Locke and Zaidi, {Sayyed Kaleem} and Campbell, {Katie M.} and Carethers, {John M.} and Jaffee, {Elizabeth M.} and {John Wherry}, E. and Soria, {Jean Charles} and Gypsyamber D{\textquoteright}souza",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2021",

month = feb,

doi = "10.1158/2159-8290.CD-20-1817",

language = "English (US)",

volume = "11",

pages = "233--236",

journal = "Cancer discovery",

issn = "2159-8274",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

TY - JOUR

T1 - Priority covid-19 vaccination for patients with cancer while vaccine supply is limited

AU - Ribas, Antoni

AU - Sengupta, Rajarshi

AU - Locke, Trevan

AU - Zaidi, Sayyed Kaleem

AU - Campbell, Katie M.

AU - Carethers, John M.

AU - Jaffee, Elizabeth M.

AU - John Wherry, E.

AU - Soria, Jean Charles

AU - D’souza, Gypsyamber

PY - 2021/2

Y1 - 2021/2

N2 - Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

AB - Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.

UR - http://www.scopus.com/inward/record.url?scp=85100804506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100804506&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-20-1817

DO - 10.1158/2159-8290.CD-20-1817

M3 - Article

C2 - 33355178

AN - SCOPUS:85100804506

SN - 2159-8274

VL - 11

SP - 233

EP - 236

JO - Cancer discovery

JF - Cancer discovery

IS - 2

ER -

Priority covid-19 vaccination for patients with cancer while vaccine supply is limited

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this